Boehringer Ingelheim

Mylan, Biocon copy inches closer to challenging Sanofi's long-suffering Lantus
Mylan, Biocon copy inches closer to challenging Sanofi's long-suffering Lantus
Fierce Pharma
Sanofi
Lantus
Eli Lilly
Boehringer Ingelheim
Mylan Labs
generics
diabetes
insulin
basal insulin
Flag link:
Boehringer Ingelheim plans to cut about 300 jobs in France
Boehringer Ingelheim plans to cut about 300 jobs in France
Yahoo/Reuters
France
Boehringer Ingelheim
layoffs
Flag link:
Boehringer dropping ex-U.S. biosimilars programs
Boehringer dropping ex-U.S. biosimilars programs
BioCentury
Boehringer Ingelheim
biosimilars
Flag link:
Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years
Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years
BioSpace
cancer
breast cancer
lung cancer
drug approvals
AstraZeneca
Takeda
Ariad Pharmaceuticals
Merck
Pfizer
Novartis
Boehringer Ingelheim
Bristol-Myers Squibb
Eli Lilly
Puma Biotechnology
Mylan
Genentech
Flag link:
Boehringer Ingelheim and Epizyme Ink Collaboration Deal With $15 Million Upfront and $280 Million in Biobucks
Boehringer Ingelheim and Epizyme Ink Collaboration Deal With $15 Million Upfront and $280 Million in Biobucks
BioSpace
cancer
R&D
drug development
Boehringer Ingelheim
Epizyme
Flag link:
Boehringer backs $33M cancer vaccine play at Switzerland's AMAL Therapeutics
Boehringer backs $33M cancer vaccine play at Switzerland's AMAL Therapeutics
Endpoints
vaccines
cancer vaccines
Boehringer Ingelheim
Amal Therapeutics
Switzerland
Flag link:
Boehringer Cites ‘Massive’ Number of Patents in Humira Biosimilar Suit
Boehringer Cites ‘Massive’ Number of Patents in Humira Biosimilar Suit
RAPS.org
Boehringer Ingelheim
AbbVie
Humira
patents
biosimilars
Flag link:
Battle Over Humira Begins in Europe as 5-Year Wait Begins in US
Battle Over Humira Begins in Europe as 5-Year Wait Begins in US
RAPS.org
Europe
AbbVie
Humira
Amgen
Samsung Bioepis
Mylan Labs
Novartis
Sandoz
Fresenius Kabi
Boehringer Ingelheim
Flag link:
New Analysis Suggests that Jardiance Could Add Years to Life Expectancy of Adults With Type 2 Diabetes and Cardiovascular Disease
New Analysis Suggests that Jardiance Could Add Years to Life Expectancy of Adults With Type 2 Diabetes and Cardiovascular Disease
CP Wire
Jardiance
Boehringer Ingelheim
Eli Lilly
diabetes
type 2 diabetes
Flag link:
New Analysis Suggests that Jardiance Could Add Years to Life Expectancy of Adults With Type 2 Diabetes and Cardiovascular Disease
Jardiance
Boehringer Ingelheim
Eli Lilly
Flag link:
Lilly, Boehringer hit heart safety mark with Januvia rival Tradjenta. Is that enough?
Lilly, Boehringer hit heart safety mark with Januvia rival Tradjenta. Is that enough?
Fierce Pharma
Boehringer Ingelheim
Eli Lilly
Tradjenta
diabetes
Flag link:
Boehringer Ingelheim joins the crowd and goes all-in on oncolytic viruses, buying ViraTherapeutics in $244M deal
Boehringer Ingelheim joins the crowd and goes all-in on oncolytic viruses, buying ViraTherapeutics in $244M deal
Endpoints
Boehringer Ingelheim
ViraTherapeutics
M&A
Flag link:
Cooperation agreement between Boehringer Ingelheim and Tsinghua University (Beijing)
Cooperation agreement between Boehringer Ingelheim and Tsinghua University (Beijing)
GoinPharma
Boehringer Ingelheim
Tsinghua University
Flag link:
Boehringer Ingelheim and Tsinghua University Collaborate to Harness the Immune System to Better Fight Infectious Diseases
Boehringer Ingelheim and Tsinghua University Collaborate to Harness the Immune System to Better Fight Infectious Diseases
CP Wire
antibiotics
Boehringer Ingelheim
drug development
Flag link:
Boehringer Ingelheim and Tsinghua University Collaborate to Harness the Immune System to Better Fight Infectious Diseases
Boehringer Ingelheim
Flag link:
Boehringer, Lilly diabetes drug Tradjenta succeeds in cardiovascular outcome trial
Boehringer, Lilly diabetes drug Tradjenta succeeds in cardiovascular outcome trial
Pharmaceutical Business Review
Boehringer Ingelheim
Eli Lilly
clinical trials
diabetes
Tradjenta
Flag link:
Boehringer Ingelheim lands option on cystic fibrosis gene therapy
Boehringer Ingelheim lands option on cystic fibrosis gene therapy
Fierce Biotech
Boehringer Ingelheim
cystic fibrosis
Oxford BioMedica
gene therapy
Flag link:
Trajenta Meets Primary Endpoint in Cardiovascular Trial
Trajenta Meets Primary Endpoint in Cardiovascular Trial
CP Wire
Boehringer Ingelheim
Eli Lilly
Trajenta
Flag link:
Trajenta Meets Primary Endpoint in Cardiovascular Trial
Boehringer Ingelheim
Eli Lilly
Trajenta
Flag link:
Boehringer Ingelheim Licenses Novel TCRm Antibody for Cancer Treatment
Boehringer Ingelheim Licenses Novel TCRm Antibody for Cancer Treatment
CP Wire
Boehringer Ingelheim
Eureka Therapeutics
monoclonal antibodies
Flag link:

Pages